Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Dezember 2017 08:36 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented

NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
08. Dezember 2017 07:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting

NEW YORK, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
16. November 2017 07:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)

NEW YORK, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
09. November 2017 16:01 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Third Quarter 2017 Financial Results

NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
01. November 2017 09:02 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting

NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
31. Oktober 2017 07:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint

Detailed results will be presented at the ASH 2017 Annual Meeting (Dec. 9-12)Based on FDA feedback, BLA filing remains on-track Conference call scheduled for today, Tuesday, October 31, 2017 at 8:30AM...
20. September 2017 07:00 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
11. September 2017 07:00 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017

NEW YORK, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
08. September 2017 07:30 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

NEW YORK, Sept. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
30. August 2017 18:10 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress

NEW YORK, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...

Vorherige Seite

Nächste Seite